Intraocular Pressure Outcomes After Lampalizumab Injections in Patients With Geographic Atrophy

• Published in: JAMA ophthalmology
• Main Authors: Bressler, Neil M, Freund, K Bailey, Bakri, Sophie J, Kim, Judy E, Ferrara, Daniela, Brittain, Christopher, Pickthorn, Karen, Lin, Hugh, Sun, Christy, Martin, Jillian
• Format: Journal Article
• Language: English
• Published: United States 01.08.2024
• ISSN: 2168-6173
• DOI: 10.1001/jamaophthalmol.2024.2061

Intraocular pressure (IOP) elevations of clinical relevance have been observed after the commonly used 0.05-mL volume for intravitreous injections. However, more recently approved intravitreous agents involve volumes from 0.07 to 0.1 mL. It is not well established whether repeated 0.1-mL intravitreous injections may result in IOP-related complications. To investigate the effect of 1 year of repeated 0.1-mL intravitreous injections on IOP outcomes. This study was a post hoc analysis of 2 clinical trials investigating the IOP safety of intravitreous lampalizumab on geographic atrophy secondary to age-related macular degeneration. Both trials were conducted between 2014 and 2018 and recruited participants who were 50 years or older and had bilateral geographic atrophy. This post hoc analysis was performed between 2018 and 2022. Intravitreous lampalizumab, 0.1 mL, every 4 weeks; lampalizumab, 0.1 mL, every 6 weeks; or sham procedure every 4 weeks or 6 weeks for 48 weeks. IOP changes in the 4-week-frequency study arms and ocular adverse events to week 48 in all arms. The hypothesis for this analysis was formulated after data collection. Among a total of 1851 participants, there was no change in mean pre-injection IOP values through 48 weeks in either arm. The adverse events glaucoma and ocular hypertension were reported for 1.8% of participants treated with lampalizumab and 1.6% of those in the sham arm. Over 1 year, IOP increases were rare and did not affect treated participants more frequently than sham arm participants. These findings support the low risk of persistent IOP increases, on average, of intravitreous 0.1-mL injection volumes administered for 1 year in a manner similar to that performed in these clinical trials. These results may be valuable in the design of future therapeutic trials considering this volume for injections particularly as more recently approved agents use volumes of 0.07 to 0.1 mL. ClinicalTrials.gov Identifiers: NCT02247479 and NCT02247531.